bioMérieux and Banyan Biomarkers announced that they have entered into a partnership. Under the terms of the agreement, bioMérieux takes an equity participation of about $7 million in Banyan Biomarkers and obtains the rights to commercialize Banyan’s proprietary tests worldwide for use in vitro diagnostics, with preferred rights for its VIDAS® immunoassays range. In addition, the two companies will continue to explore co-development opportunities in the area of TBI and critical care. By combining Banyan’s innovative biomarkers with bioMérieux leading position in IVD at the critical care and its global commercial footprint, both companies aim at bringing to clinicians the first FDA-approved blood-based automated test for TBI.